Company Overview
Company Type: Public Company
Website: turnstonebio.com
Number of Employees: 112
Ticker: TSBX (NasdaqGM)
Year Founded: 2014


Business Description
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company’s lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Financial Information (Currency: CAD, in mm) 
Total Revenue
54.7
Market Capitalization
58.7
TEV/Total Revenue
4.3x
EBITDA
(57.3)
Total Enterprise Value
232.4
TEV/EBITDA
NM
EBIT
(62.4)
Cash & ST Invst.
67.3
P/Diluted EPS Before Extra
NM
Net Income
(70.1)
Total Debt
5.8
Price/Tang BV
NM
Capital Expenditure
(4.7)
Total Assets
102.3
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.88)
(0.82)
(5.42)
(4.02)
(3.80)
Revenue (mm)
0.00
0.00
26.40
0.00
0.00
EBITDA (mm)
-
-
(78.22)
-
-

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
9.35x
TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
23.25
Potential Upside
626.50%


Key Professionals
Name
Title
Farah, Sammy J.
President, CEO & Director
Ramanan, Venkat 
Chief Financial Officer
Chiruvolu, Vijay 
Interim Chief Technology Officer
Abbot, Stewart 
Chief Scientific Officer
Campisi, P. Joseph
Chief Legal Officer
Azmat, Saryah 
Chief Business Officer
Burgess, Michael F.
Interim Chief Medical Officer & Executive Director

Key Board Members
Name
Title
Davis, Jerel C.
Independent Chairman of the Board
Farah, Sammy J.
President, CEO & Director
Burgess, Michael F.
Interim Chief Medical Officer & Executive Director
Brenner, Malcolm K.
Member of Scientific Advisory Board
Dubensky, Thomas W.
Member of the Scientific Advisory Board
Fox, Bernard A.
Member of the Scientific Advisory Board
Gould, Robert J.
Independent Director
Gupta, Rishi
Independent Director
Hill, Adrian 
Member of the Scientific Advisory Board
Machado, C. Patrick
Independent Director
Melcher, Alan 
Member of the Scientific Advisory Board
Mule, James J.
Member of the Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
9310 Athena Circle Suite 300 | LA Jolla, CA | 92037 | United States
Phone: 347-897-5988   

Current and Pending Investors
Brace Pharma Capital, CaaS Capital Management LP, Citadel Advisors LLC, Eventide Asset Management, LLC, F Prime, Inc., Fight Against Cancer Innovation Trust, Impresa Management LLC, JM Family Enterprises, Inc., Northleaf Capital Partners Ltd., OrbiMed Advisors LLC, PFM Health Sciences, LP, Point72 Asset Management, L.P., Ridgeback Capital Management LLC, Sectoral Asset Management Inc., Sixty Degree Capital, Inc., Takeda Ventures, Inc., Versant Venture Management, LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 3.20
Market Cap (mm)
73.1
Open
 2.57
Shares Out. (mm)
22.8
Previous Close
 3.20
Float %
71.6%
Change on Day
0.63
Shares Sold Short (mm)
0.2
Change % on Day
24.5%
Dividend Yield %
-
Day High/Low
 3.23/ 2.56
Diluted EPS Excl. Extra Items
(25.65)
52 wk High/Low
 18.05/ 2.50
P/Diluted EPS Before Extra
NM
Volume (mm)
0.06
Avg 3M Dly Vlm (mm)
0.11
Beta 5Y
-


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)


Index Membership
S&P Completion Index (CI);S&P TMI Index;S&P Completion Index (CI) Health Care (US Dollar);S&P TMI Health Care


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Myst Therapeutics, Inc.
Myst Therapeutics, Inc. operates as a biotechnology company which focuses on development and commercialization of novel cancer immunotherapy products from a patient’s own immune system to destroy cancer cells. The company develops adoptive cell therapy utilizing T cells from tumors and peripheral blood. Myst Therapeutics, Inc. was founded in 2019 and is based in Los Angeles, California.

United States and Canada
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-25-2023
-
Shelf Registration
Target
Turnstone Biologics Corp. (NasdaqGM:TSBX)


60.39
Jun-12-2023
Jul-20-2023
Public Offering
Target
Turnstone Biologics Corp. (NasdaqGM:TSBX)


80.00
Jun-29-2021
Jul-14-2021
Private Placement
Target
Turnstone Biologics Corp. (NasdaqGM:TSBX)
Versant Venture Management, LLC,OrbiMed Advisors LLC,Impresa Management LLC,PFM Health Sciences, LP,Eventide Asset Management, LLC,Ridgeback Capital Management LLC,Takeda Ventures, Inc.,CaaS Capital Management LP,JM Family Enterprises, Inc.,Northleaf Capital Partners Ltd.,Citadel Advisors LLC,Stamford Harbor Capital, L.P. (nka:Point72 Asset Management, L.P.),Sectoral Asset Management Inc.,F Prime, Inc.,Sixty Degree Capital, Inc.,Brace Pharma Capital Buyer Funds:Citadel Multi-Strategy Equities Master Fund Ltd.

80.00
Jan-20-2021
Jan-20-2021
Merger/Acquisition
Buyer
Myst Therapeutics, Inc.
Turnstone Biologics Corp. (NasdaqGM:TSBX)

-
Jan-04-2019
Jan-18-2019
Private Placement
Target
Turnstone Biologics Corp. (NasdaqGM:TSBX)


42.10
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-18-2023
Index Constituent Adds
Turnstone Biologics Corp.(NasdaqGM:TSBX) added to S&P TMI Index
Jul-25-2023
Changes in Company Bylaws/Rules
Turnstone Biologics Corp. Announces Amendments to Articles of Incorporation or Bylaws
Jul-25-2023
Shelf Registration Filings
Turnstone Biologics Corp. has filed a Shelf Registration in the amount of $60.39078 million.
Jul-24-2023
Index Constituent Adds
Turnstone Biologics Corp.(NasdaqGM:TSBX) added to NASDAQ Composite Index
Jul-20-2023
IPOs
Turnstone Biologics Corp. has completed an IPO in the amount of $80.000004 million.


Advisors
Most Recent Auditor
Ernst & Young LLP
Public Offering Advisors
Cooley LLP, Ernst & Young LLP


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
New Constructs, LLC

Sep 29, 2023 08:30 PM
TSBX
TSBX: Forensic Stock Earnings & Valuation
Reports
6
Piper Sandler Companies
Catanzaro, Joseph Michael
Sep 04, 2023 03:07 PM
TSBX
Model Update
EPS Estimates*
6
Piper Sandler Companies
Catanzaro, Joseph Michael
Aug 15, 2023 01:55 AM
TSBX
Initiating At OW: Rocking The Boat With Solid Tumor-Selective Cell Therapy
Initiation of Coverage*
44


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Versant Venture Management, LLC

3,381,692

14.80

9.2

Jul-25-2023


OrbiMed Advisors LLC

3,099,265

13.57

8.4

Jul-21-2023


FMR LLC

2,918,787

12.78

7.9

Jul-25-2023


Impresa Management LLC

1,133,987

4.96

3.1

Jul-25-2023


FACIT Inc.

1,020,636

4.47

2.8

Jul-21-2023


Point72 Asset Management, L.P.

833,333

3.65

2.3

Jul-26-2023


PFM Health Sciences, LP

549,980

2.41

1.5

Jul-21-2023


The Vanguard Group, Inc.

70,000

0.31

0.2

Aug-31-2023


Geode Capital Management, LLC

9,632

0.04

0.0

Aug-31-2023


Mirae Asset Global Investments Co., Ltd.

1

0.00

0.0

Sep-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Versant Venture Management, LLC
3,381,692
3,381,692
OrbiMed Advisors LLC
3,099,265
3,099,265
FMR LLC
2,918,787
2,918,787
Impresa Management LLC
1,133,987
1,133,987
Point72 Asset Management, L.P.
833,333
833,333

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
TIDAL-01 (Future), TIDAL-02 (Future)


Upcoming Events
Date/Time
Type
Nov-01-2023
Conferences
Nov-04-2023
Company Conference Presentations
Dec-01-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-01-2023
Jun-30-2023
Turnstone Biologics Corp. (NasdaqGM:TSBX)
SEC
10-Q
8 MB
Jul-25-2023
-
Turnstone Biologics Corp. (NasdaqGM:TSBX)
SEC
S-8
93 KB
Jul-25-2023
Jul-25-2023
Turnstone Biologics Corp. (NasdaqGM:TSBX)
SEC
8-K (5.03, 9.01)
176 KB
Jul-24-2023
-
Turnstone Biologics Corp. (NasdaqGM:TSBX)
SEC
424B4
6 MB
Jul-20-2023
-
Turnstone Biologics Corp. (NasdaqGM:TSBX)
SEC
S-1MEF
64 KB
Jul-17-2023
-
Turnstone Biologics Corp. (NasdaqGM:TSBX)
SEC
8-A12B
14 KB
Jul-17-2023
-
Turnstone Biologics Corp. (NasdaqGM:TSBX)
SEC
S-1/A
7 MB
Jun-26-2023
-
Turnstone Biologics Corp. (NasdaqGM:TSBX)
SEC
S-1/A
7 MB
Jun-12-2023
-
Turnstone Biologics Corp. (NasdaqGM:TSBX)
SEC
S-1
9 MB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Versant Venture Management, LLC
Jul-25-2023
Common Stock
3,156,692
0
Derivative Exercise and Retained Stock
1,402.97
Form 4
-
Jul-25-2023
Common Stock
2,528,864
0
Derivative Exercise and Retained Stock
-
Form 4
-
Jul-25-2023
Common Stock
192,458
0
Derivative Exercise and Retained Stock
-
Form 4
-
Jul-25-2023
Common Stock
84,313
0
Derivative Exercise and Retained Stock
-
Form 4
-
Jul-25-2023
Common Stock
76,067
0
Derivative Exercise and Retained Stock
-
Form 4
-
Jul-25-2023
Common Stock
274,990
0
Derivative Exercise and Retained Stock
-
Form 4
Versant Venture Management, LLC
Jul-25-2023
Common Stock
225,000
3,693,006
Private Acquisition
7.13
Form 4
-
Jul-25-2023
Common Stock
197,458
3,240,949
Private Acquisition
-
Form 4
-
Jul-25-2023
Common Stock
15,028
246,660
Private Acquisition
-
Form 4
-
Jul-25-2023
Common Stock
6,575
107,918
Private Acquisition
-
Form 4
-
Jul-25-2023
Common Stock
5,939
97,479
Private Acquisition
-
Form 4
Impresa Management LLC
Jul-25-2023
Common Stock
1,133,987
-
Derivative Exercise and Retained Stock
New
Form 4
-
Jul-25-2023
Common Stock
91,663
-
Derivative Exercise and Retained Stock
-
Form 4
-
Jul-25-2023
Common Stock
106,496
-
Derivative Exercise and Retained Stock
-
Form 4
-
Jul-25-2023
Common Stock
150,809
-
Derivative Exercise and Retained Stock
-
Form 4
-
Jul-25-2023
Common Stock
483,684
-
Derivative Exercise and Retained Stock
-
Form 4
-
Jul-25-2023
Common Stock
296,396
-
Derivative Exercise and Retained Stock
-
Form 4
-
Jul-25-2023
Common Stock
4,939
-
Derivative Exercise and Retained Stock
-
Form 4
OrbiMed Advisors LLC
Jul-20-2023
Common Stock
2,682,599
0
Derivative Exercise and Retained Stock
643.82
Form 4
OrbiMed Advisors LLC
Jul-20-2023
Common Stock
416,666
6,838,889
Private Acquisition
15.53
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Davis, Jerel C.
Independent Chairman of the Board
347-897-5988
-
jdavis@versantventures.com
Farah, Sammy J.
President, CEO & Director
347-897-5988
-

Burgess, Michael F.
Interim Chief Medical Officer & Executive Director
347-897-5988
-

Brenner, Malcolm K.
Member of Scientific Advisory Board
347-897-5988
-
mbrenner@bcm.edu
Dubensky, Thomas W.
Member of the Scientific Advisory Board
347-897-5988
-

Fox, Bernard A.
Member of the Scientific Advisory Board
347-897-5988
-

Gould, Robert J.
Independent Director
(617) 651-8851
-
rg@khoslaventures.com
Gupta, Rishi
Independent Director
347-897-5988
-
gupar@orbimed.com
Hill, Adrian 
Member of the Scientific Advisory Board
347-897-5988
-

Machado, C. Patrick
Independent Director
347-897-5988
-

Melcher, Alan 
Member of the Scientific Advisory Board
347-897-5988
-
Alan.Melcher@icr.ac.uk
Mule, James J.
Member of the Scientific Advisory Board
347-897-5988
-
james.mule@moffitt.org
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Farah, Sammy J.
President, CEO & Director
347-897-5988
-

Ramanan, Venkat 
Chief Financial Officer
347-897-5988
-

Chiruvolu, Vijay 
Interim Chief Technology Officer
347-897-5988
-

Abbot, Stewart 
Chief Scientific Officer
347-897-5988
-

Campisi, P. Joseph
Chief Legal Officer
347-897-5988
-

Azmat, Saryah 
Chief Business Officer
347-897-5988
-

Burgess, Michael F.
Interim Chief Medical Officer & Executive Director
347-897-5988
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
